ABOUT US-Guangdong Hecin Scientific,Inc.

About Us

Founded in 2015, Guangdong Hecin Scientific, Inc.(Hecin) is a specialized diagnosis solution supplier of respiratory healthcare and scientific research. Located in the IUR( Industry-university-Research ) Base of the State Key Laboratory of Respiratory Diseases, we dedicate to innovative research and development of respiratory infection diagnosis, and have owned the largest respiratory virus&bacterial biobank in China,expanded self-owned Biosafety Level 2 Laboratory, serving as a professional provider of pathogen diagnostic assay; POCT device; reference panel; PCR core raw material. With the mission of safeguarding human respiratory health, Hecin always adhere to independent research and development in order to make in-vitro diagnosis more accurate, more sensitive, more convenient and faster. Committed to be a comprehensive diagnostic provider, our aim is to promote a healthy respiratory system for all.

2015 year

Establish in

600 +

Example virus strain

8000 thousand

Sales share

50 +

Export region

Our Mission

Ensuring human respiratory health

Our Vision

Comprehensive provider of diagnostic solution for respiratory diseases

Our Value

Pursuing excellence, technology-oriented, honest and trustworthy, embrace responsibility with passion

Our Mission

Ensuring human respiratory health

Our Vision

Comprehensive provider of diagnostic solution for respiratory diseases

Our Value

Pursuing excellence, technology-oriented, honest and trustworthy, embrace responsibility with passion

Development history

Hecin focuses on the R&D, production, and sales of diagnostic solution for respiratory infectious diseases

2015

• Company establishment
• Presided over the Guangzhou University special project
• Got the first financing 30 million

2016

• Rated as a Class A medical device manufacturing enterprise
• Selected as a specialized, refined, and innovative enterprise in Guangzhou
• Launching rapid PCR instrument reagents
• Received support from Guangzhou laboratory and Guangdong emergency research projects

2017

• Got the second financing 40 million
• Participate in major projects of the Ministry of Science and Technology

2018

• Participated in two major special projects of the Ministry of Science and Technology and presided over one of the sub-projects.

2019

•Obtained 9 Class III registration certificates (2018-2019)
•Selected into the National Major Talent Project (Li Xiaofeng)
•Achieve sales of company products for the first time

2020

• 13 Class III clinical diagnostic products are undergoing clinical trials
•2019Covid detection products are supported by the Ministry of Science and Technology
•2019Covid detection products are certified and launched
•Recognized as Guangdong Provincial Engineering Technology Research Center
•Completed Series B financing of RMB 83 million

2021

• Rated as a Class A medical device manufacturer
• Selected as Guangzhou Specialized and New Enterprise
• Launched rapid PCR instrument reagent
• Received support from Guangzhou Municipal Laboratory and Guangdong Provincial Emergency Research Project

2022

•The Influ A and Influ B and Adenovirus Nucleic Acid Detection Reagent obtained the National Class III Medical Device Registration Certificate
•The company’s sales exceeded RMB 200 million in the first quarter

2023

• Continuously rated as a Class A medical device manufacturer
• Selected as a specialized and new enterprise in Guangdong Province
• Selected into the list of the top 100 high-tech companies to be listed in Guangzhou
• SP/MP/HI nucleic acid test kit(Streptococcus pneumoniae/Mycoplasma pneumonia /Haemophilus influenzae combo test) obtained Class III registration certificate

2015

2016

2017

2018

2019

2020

2021

2022

2023

Honors

With a mission is to ensure human respiratory health

GDMPA High and new technology enterprises Trade organization member Competition award certificate

GDMPA 2020 Guangdong Quality credit Class A medical device manufacturer

GDMPA 2021 Guangdong Quality credit Class A medical device manufacturer

2022 Guangdong Quality credit Class A medical device manufacturer

Our market

A comprehensive provider of diagnostic solution for respiratory pathogens

The international market has been opened up, and our products have been exported to more than 70 countries and regions. Affected by the COVID-19, the demand respiratory diagnosis will continue to increase in the next 3-5 years all round the world.

Europe Asia Africa North America Oceania South America

Europe

Spain, Italy, Hungary, Portugal, Switzerland, Germany, Poland, Kosovo, Morocco, Netherlands, Denmark, Lithuania, Ukraine, Czech Republic, Austria, Belgium, Luxembourg, Monaco, Serbia, Slovenia, Croatia, Russia

Europe

Asia

Japan, Türkiye, Indonesia, Philippines, Thailand, Singapore, Pakistan, India, Bangladesh, Malaysia, Saudi Arabia

Africa

South Africa, Tanzania, Togo, Kenya, Tunisia, Algeria

North America

Canada, Dominica, Mexico, Guatemala

Oceania

Tonga, Australia

South America

Brazil, Colombia, Ecuador, Peru, Bolivia, Chile, Uruguay, Venezuela, Paraguay